Phibro Animal Health Corp (PAHC): EBITDA
$245.91M
Year ended 2026-06-30
+32.4%
3-year compound annual growth
+18.2%
5-year compound annual growth
+8.5%
10-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $245.91M | +57.6% | 2026-08-26, From 2025-07-01 |
| 2025-06-30 | $156.07M | +74.4% | 2026-08-26, From 2024-07-01 |
| 2024-06-30 | $89.49M | -15.5% | 2026-08-26, From 2023-07-01 |
| 2023-06-30 | $105.86M | -5.2% | 2025-08-27, From 2022-07-01 |
| 2022-06-30 | $111.69M | +4.6% | 2024-08-28, From 2021-07-01 |
| 2021-06-30 | $106.75M | +5.1% | 2023-08-30, From 2020-07-01 |
| 2020-06-30 | $101.53M | -8.4% | 2022-08-24, From 2019-07-01 |
| 2019-06-30 | $110.79M | -12.0% | 2021-08-25, From 2018-07-01 |
| 2018-06-30 | $125.87M | +1.6% | 2020-08-26, From 2017-07-01 |
| 2017-06-30 | $123.94M | +13.5% | 2019-08-27, From 2016-07-01 |
| 2016-06-30 | $109.20M | -0.1% | 2018-08-27, From 2015-07-01 |
| 2015-06-30 | $109.27M | +28.2% | 2017-08-30, From 2014-07-01 |
| 2014-06-30 | $85.25M | +12.5% | 2016-08-29, From 2013-07-01 |
| 2013-06-30 | $75.75M | +13.3% | 2015-09-10, From 2012-07-01 |
| 2012-06-30 | $66.85M | n/a | 2014-09-18, From 2011-07-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $245.91M | +57.6% |
| Alkermes plc. (ALKS) | 2025-12-31 | $281.12M | -37.4% |
| PTC Therapeutics, Inc. (PTCT) | 2025-12-31 | $905.75M | n/m |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $272.00M | +403.7% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $340.68M | -7.2% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$655.26M | n/m |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | -$298.59M | n/m |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $202.51M | +196.4% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $120.55M | n/m |
Compare PAHC, ALKS, PTCT, INDV side by side · Screen every company in Pharmaceutical Preparations ↗